A timeline of initial tumor growth, tumor reduction after IRE treatment, IFNγ expression and its stimulation of PD-1/PD-L1, activation/suppression of pattern recognition receptors, and the TGF-β pathway would help the field develop co-therapy targets and design improved clinical trials. Here, TGFB1 is linked to neoplasm.